Skip to main content Back to Top


Acamprosate Calcium Tablets

Reason for the Shortage

    • Glenmark Pharmaceuticals could not provide a reason for the shortage.
    • Mylan could not provide a reason for the shortage.
    • Actavis discontinued Campral tablets in 2014.

Available Products

    • Acamprosate calcium oral tablet, Glenmark, 333 mg, bottle, 180 count, NDC 68462-0435-18
    • Acamprosate calcium oral tablet, Mylan, 333 mg, bottle, 180 count, NDC 00378-6333-80
    • Acamprosate calcium oral tablet, Mylan Institutional, 333 mg, unit-dose 50 count, NDC 51079-0241-06

Estimated Resupply Dates

    • All presentations are currently available.


Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 30, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins